This opinion in the WSJ pinpoints well the reason that Mylan has been increasing the price of its EpiPen: :the steady Mylan rise is hard to read as anything other than inevitable when a billion-dollar market is cornered by one supplier."
The writer also questions the wisdom of Hillary Clinton's claim that "the EpiPen price hikes show the need for price controls" and her proposal to "require drug makers to 'prove that any [increases in price] are linked to additional patient benefits and better value.'” Should we require Nike to to prove that any increase in price are linked to additional benefits and better value when they sell running shoes?
No comments:
Post a Comment